NCT00363584已完成3 期
A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 360
- 试验地点
- 46
- 主要终点
- Survival at 2 years
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving capecitabine after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the tumor may not need more treatment until it progresses. In this case, observation may be sufficient. It is not yet known whether capecitabine is more effective than observation in treating biliary tract cancer.
PURPOSE: This randomized phase III trial is studying capecitabine to see how well it works compared with observation in treating patients with biliary tract cancer.
详细描述
OBJECTIVES:
Primary
- To determine whether adjuvant chemotherapy with capecitabine has any effect on 2-year survival compared to expectant treatment alone (observation) in patients who have undergone a macroscopically complete surgical resection of a biliary tract cancer.
Secondary
- To compare capecitabine versus observation in terms of 5-year survival, relapse-free survival, toxicity, quality of life, and health economics.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed biliary tract cancer (including intrahepatic or extrahepatic/hilar cholangiocarcinoma or muscle invasive gallbladder cancer or cancer of the distal bile duct)
- •Must have undergone a radical surgical approach which includes liver resection, pancreatic resection, or less commonly both
- •Patients with pathological evidence of microscopic involvement of the margins of the excised specimen are eligible as long as resection is macroscopically complete
- •Must be able to start treatment within 12 weeks of surgery
- •No pancreatic or periampullary cancer
- •No mucosal gallbladder cancer
- •PATIENT CHARACTERISTICS:
- •ECOG performance status 0-2
- •Urea < 1.5 times upper limit of normal (ULN)
- •Creatinine < 1.5 times ULN
- •Glomerular filtration rate ≥ 60 mL/min (if < 60 mL/min, adequate renal function for capecitabine must be confirmed by isotope EDTA)
- •Hemoglobin ≥ 10 g/dL
- •WBC ≥ 3,000/mm³
- •Absolute neutrophil count ≥ 1,500/mm³
- •Platelet count ≥ 100,000/mm³
- •Bilirubin ≤ 3 times ULN
- •ALT and AST ≤ 5 times ULN
- •Adequate surgical biliary drainage with no evidence of infection
- •Not pregnant or nursing
- •Negative pregnancy test for women of childbearing age and childbearing potential
- •Fertile patients must use effective contraception during study treatment and for at least 3 months after study treatment has ended
- •Must provide written informed consent
- •No history of other malignant diseases within the past 5 years other than adequately treated nonmelanoma skin cancer or in situ carcinoma of the uterine cervix
- •No serious co-existing medical condition likely to interfere with protocol treatment, including a potential serious infection
- •No evidence of significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial
- •No psychological, familial, sociological, or geographical factors considered likely to preclude study compliance
- •No other serious uncontrolled medical conditions
- •No unresolved biliary tree obstruction
- •PRIOR CONCURRENT THERAPY:
- •See Disease Characteristics
- •Completely recovered from prior surgery
- •No use of other investigational agents within 28 days prior to and during study treatment
- •No prior chemotherapy or radiotherapy for biliary tract cancer
- •No other concurrent anticancer chemotherapy, radiotherapy, or investigational agent
排除标准
- 未提供
结局指标
主要结局
Survival at 2 years
次要结局
- Survival at 5 years
- Relapse-free survival
- Toxicity
- Quality of life
- Health economics
研究者
研究点 (46)
Loading locations...
相似试验
已完成
1 期
Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic CancerPeriampullary AdenocarcinomaPancreatic CancerNCT00983268Vanderbilt-Ingram Cancer Center21
进行中（未招募）
3 期
Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By SurgeryBreast CancerNCT00301925Institute of Cancer Research, United Kingdom4,400
已完成
2 期
Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or ChemoHead and Neck CancerNCT00258310Barbara Ann Karmanos Cancer Institute35
撤回
2 期
S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck CancerRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the OropharynxNCT00095641SWOG Cancer Research Network
已完成
2 期
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and NeckMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaStage IV Verrucous Carcinoma of the LarynxRecurrent Verrucous Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Salivary Gland CancerRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the OropharynxStage IV Squamous Cell Carcinoma of the LarynxStage IV Squamous Cell Carcinoma of the Lip and Oral CavityHead and Neck CancerStage IV Squamous Cell Carcinoma of the OropharynxRecurrent Verrucous Carcinoma of the Oral CavitySalivary Gland Squamous Cell CarcinomaStage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityStage IV Salivary Gland CancerStage IV Squamous Cell Carcinoma of the HypopharynxStage IV Verrucous Carcinoma of the Oral CavityNCT01044433Abramson Cancer Center at Penn Medicine44